Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you. A shiny sun and crispy, cool air are enveloping the Pharmalot campus, where our short person is hunched over a laptop once again and our official mascot has settled in for another snooze. As for us, we are in the Pharmalot cafeteria waiting for the coffee kettle to boil so we can indulge in another cup of stimulation. Our choice today is coconut, for those tracking this sort of thing. Meanwhile, here are a few items of interest to help you on your journey. We hope you have a productive day and, of course, stay safe. …

The U.S. will buy 100 million additional shots of the Moderna (MRNA) Covid-19 vaccine — doubling its initial order of the vaccine, which the FDA is expected to authorize later this month, Politico says. The expanded order would ensure continuous vaccine delivery through the end of June 2021, at a total cost of $3.2 billion. Meanwhile, Pfizer (PFE) is still negotiating with the U.S. to provide 100 million more doses of its vaccine in 2021, Reuters notes. In July, the U.S. agreed to pay $1.95 billion for 100 million doses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.